Myeloproliferative Neoplasms Treatment Market
Overview:
Myeloproliferative neoplasms are known as rare blood cancers that caused excessive production of red blood cells, platelets or white blood cells in bone marrow of humans. Due to the excessive production of blood cells, somatic mutation is known to take place. For instance, chronic myeloproliferative diseases result from overproduction of Janus kinase 2 (JAK2). There are drug classes indicated towards myeloproliferative neoplasm treatment, which are tyrosine kinase inhibitor, demethylation agents, JAK2 inhibitor, and multikinase inhibitor among various others.
𝐓𝐨 𝐆𝐞𝐭 𝐌𝐨𝐫𝐞 𝐁𝐮𝐬𝐢𝐧𝐞𝐬𝐬 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐞𝐬 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐓𝐡𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭: @ https://www.coherentmarketinsights.com/insight/request-sample/930
Market Drivers:
Growing focus of market players on approvals for new products is expected to propel growth of the global myeloproliferative neoplasm treatment market during the forecast period. For instance, the U.S. Food and Drug Administration (FDA) granted Supplemntal New Drug Application approval to Takeda Pharmaceutical Company Ltd. in December 2020 for its ponatibib (Iclusig) developed for treatment of patients suffering from chronic-phase chronic myeloid leukemia (CML) with resistance.
In July 2019, the U.S. FDA granted approval to Pfizer Inc. for its RUXIENCE (rituximab-pvvr) to be used in treatment of adult patients suffering from non-Hodglin’s lymphoma (NHL), granulomatosis with polyangitis (GPA), microscopic polyangiitis (MPS) and chronic lymphocytic leukemia (CLL).
Moreover, key players in the market are increasingly adoption various inorganic growth strategies such as mergers and acquisitions for strengthening their market presence, and this projected to boost growth of the global myeloproliferative neoplasm treatment market during the forecast period. For instance, Abbivie, Inc. completed acquisition of Allergan, a leading pharmaceutical firm, in June 2019, due to which the R&D funding capacity of Abbivie Inc. improved allowing it to continue focus and investment on R&D in pharmaceutical.
𝐃𝐨 𝐘𝐨𝐮 𝐇𝐚𝐯𝐞 𝐒𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐑𝐞𝐪𝐮𝐢𝐫𝐞𝐦𝐞𝐧𝐭? 𝐀𝐬𝐤 𝐓𝐨 𝐎𝐮𝐫 𝐄𝐱𝐩𝐞𝐫𝐭𝐬: https://www.coherentmarketinsights.com/insight/talk-to-analyst/930
Impact of COVID-19:
The virus outbreak of COVID-19 in China affected more than 200 countries around the world. Several industries were adversely impacted by the virus outbreak as many countries imposed countrywide lockdown regulations to control the virus spread. Various market activities such as manufacturing, supply chains and distribution operations were impacted by the pandemic. As the transportation operations were disrupted under the lockdown regulations, several markets including the one in discussion were adversely impacted by the COVID-19 pandemic.
Major market players are focused on clinical trials to develop new combined treatment approach for COVID-19 treatment. For instance, Novartis International AG collaborated woth Incyte Corporation and announced a Phase III clinical trial in April 2020, designed for evaluation of Jakavi (ruxolitinib) for cytokine storm treatment that may cause fatal respiratory complications in COVID-19 patients.
Key Takeaways:
- The global myeloproliferative neoplasm drugs market is estimated to show a CAGR of 3.9% during the forecast period. This can be attributed to rise in cases of myeloproliferative neoplasm along with availability of pipeline products.
- Tyrosine kinase inhibitor segment, among Drug Class is anticipated to witness strong growth in the global myeloproliferative neoplasm treatment market during the forecast period due to growing focus of market players on gaining regulatory approvals for new drugs designed for myeloproliferative neoplasm treatment.
Key Takeaways:
Major Players functioning in the global myeloproliferative neoplasm treatment market are Constellation Pharmaceuticals, Novartis International AG, AbbVie Inc., PharmaEssentia Corporation, Imago BioSciences, Bristol – Myers Squibb, CTI BioPharma Corp., Pfizer, Inc., Sierra Oncology, Inc., Takeda Pharmaceutical Company Limited, Gamida Cell, Incyte, F. Hoffmann-La Roche AG, Johnson & Johnson, and Teva Pharmaceutical Industries Ltd.
𝐆𝐫𝐚𝐛 𝐭𝐡𝐞 𝐎𝐟𝐟𝐞𝐫 𝐚𝐧𝐝 𝐆𝐞𝐭 𝐅𝐋𝐀𝐓 𝟑𝟎% 𝐃𝐢𝐬𝐜𝐨𝐮𝐧𝐭 𝐨𝐧 𝐓𝐡𝐢𝐬 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭 𝟐𝟎𝟐𝟐-𝟐𝟎𝟐𝟖 @ https://www.coherentmarketinsights.com/promo/buynow/930
Table of Contents
- Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
- Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Indication
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
- Coherent Opportunity Map (COM)
- Report Description
- Market Dynamics, Regulations, and Trends Analysis
- Drivers
- Restraints
- Opportunities
- Impact Analysis
- Key Developments
- Product Launch/ Approvals
- Mergers, Acquisition & Collaboration
- Pipeline Analysis
- Regulatory Scenario
- PEST Analysis
- Epidemiology
- Market Share Analysis
- Global Myeloproliferative Neoplasm Drugs Market – Impact of Coronavirus (Covid-19) Pandemic
- Supply Side and Demand Side Analysis
- COVID-19 Impact on Overall Healthcare Sector
- COVID-19 Impact on Clinical Trials and Drug Development
- COVID-19 Impact on Cancer Treatment
- Global Myeloproliferative Neoplasm Drugs Market, By Drug Class, 2016–2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017–2027
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Segment Trends
- Demethylation Agents
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Tyrosine kinase Inhibitor
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Multikinase Inhibitors
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- JAK2 Inhibitor
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Others
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Demethylation Agents
- Introduction
- Global Myeloproliferative Neoplasm Drugs Market, By Indication, 2016 – 2027, (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017– 2027
- Segment Trends
- Ph+ Chronic myelogenous leukemia (CML)
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Ph- Myeloproliferative Neoplasms (MPNs)
- Introduction
- Market size and forecast, and Y-o-Y Growth, 2020-2027, (US$ Mn)
- Myelofibrosis (MF)
- Polycythemia Vera (PV)
- Essential thrombocythemia (ET)
- Ph+ Chronic myelogenous leukemia (CML)
- Introduction
- Global Myeloproliferative Neoplasm Drugs Market, By Distribution Channel, 2016–2027 (US$ Mn)
- Introduction
- Market Share Analysis, 2020 and 2027 (%)
- Y-o-Y Growth Analysis, 2017– 2027
- Segment Trends
- Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
- Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
- Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020 – 2027, (US$ Mn)
- Hospital Pharmacies
- Introduction
View Press Release: https://www.coherentmarketinsights.com/press-release/myeloproliferative-neoplasm-drugs-market-3663
𝗔𝗯𝗼𝘂𝘁 𝗨𝗦:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
𝗖𝗼𝗻𝘁𝗮𝗰𝘁 𝗨𝘀:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200 Seattle, WA 98154, U.S.
Email: sales@coherentmarketinsights.com
United States of America: +1-206-701-6702
United Kingdom: +44-020-8133-4027
Japan: +050-5539-1737
India: +91-848-285-0837